Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation

BACKGROUND: STK11 mutation (STK11(m)) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated with inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance of STK11(m) in stage III NSCLC pts treated with concurrent chemoradiation (CCRT) wit...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Josiah, Yan, Melissa, Yu, Nanmeng, Chennamadhavuni, Adithya, Furqan, Muhammad, Mott, Sarah L., Loeffler, Bradley T., Kruser, Timothy, Sita, Timothy L., Feldman, Lawrence, Nguyen, Ryan, Pasquinelli, Mary, Hanna, Nasser H., Abu Hejleh, Taher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435393/
https://www.ncbi.nlm.nih.gov/pubmed/34584860
http://dx.doi.org/10.21037/tlcr-21-177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435393/
https://www.ncbi.nlm.nih.gov/pubmed/34584860
http://dx.doi.org/10.21037/tlcr-21-177

Ejemplares similares